Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tris Pharma, Inc.

https://www.trispharma.com/

Latest From Tris Pharma, Inc.

iRhythm Is ‘Encouraged’ By Recent Reimbursement Discussions With Novitas

The company provided another update on its ongoing efforts to secure adequate Medicare reimbursement for long-term continuous cardiac monitoring.

Reimbursement Patient Monitoring

Advicenne Hastens EU Approval For Sibnayal By Withdrawing Orphan Designation

 Advicenne withdrew its orphan drug designation application for Sibnayal over concerns that a key study was not designed to compare the product with the standard of care.

Europe Rare Diseases

Deal Watch: AZ, Alchemab To Study Immune Response For Novel Cancer Targets

Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.

Deals Business Strategies

Reimbursement Dispute Between Novitas And iRhythm Hits An Impasse

Local Medicare carrier Novitas raised its reimbursement rates for continuous cardiac monitoring, but iRhythm has concluded the rates are still too low and is preparing to discontinue serving this Medicare segment.

Reimbursement Cardiovascular
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Other Names / Subsidiaries
    • NextWave Pharmaceuticals
    • Park Therapeutics, Inc.
UsernamePublicRestriction

Register